MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood-2013-05-504555

Медицинская библиотека · Blood · 2014

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

Marty Caroline, Saint-Martin Cécile, Pecquet Christian, Grosjean Sarah, Saliba Joseph, Mouton Céline, Leroy Emilie, Harutyunyan Ashot S, Abgrall Jean-François, Favier Rémi, Toussaint Aurélie, Solary Eric, Kralovics Robert, Constantinescu Stefan N, Najman Albert, Vainchenker William, Plo Isabelle, Bellanné-Chantelot Christine

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The main molecular basis of essential thrombocythemia and hereditary thrombocytosis is acquired, and germ-line-activating mutations affect the thrombopoietin signaling axis. We have identified 2 families with hereditary thrombocytosis presenting novel heterozygous germ-line mutations of JAK2. One family carries the JAK2 R867Q mutation located in the kinase domain, whereas the other presents 2 JAK2 mutations, S755R/R938Q, located in cis in both the pseudokinase and kinase domains. Expression of Janus kinase 2 (JAK2) R867Q and S755R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human receptor of erythropoietin cells. Interestingly, both Ba/F3-MPL cells expressing the mutants and platelets from patients displayed thrombopoietin-independent phosphorylation of signal transducer and activator of transcription 1. The JAK2 R867Q and S755R/R938Q proteins had significantly longer half-lives compared with JAK2 V617F. The longer half-lives correlated with increased binding to the heat shock protein 90 (HSP90) chaperone and with higher MPL cell-surface expression. Moreover, these mutants were less sensitive to JAK2 and HSP90 inhibitors than JAK2 V617F. Our results suggest that the mutations in the kinase domain of JAK2 may confer a weak activation of signaling specifically dependent on MPL while inducing a decreased sensitivity to clinically available JAK2 inhibitors.

Для цитирования: Marty Caroline, Saint-Martin Cécile, Pecquet Christian, Grosjean Sarah, Saliba Joseph, Mouton Céline, Leroy Emilie, Harutyunyan Ashot S, Abgrall Jean-François, Favier Rémi, Toussaint Aurélie, Solary Eric, Kralovics Robert, Constantinescu Stefan N, Najman Albert, Vainchenker William, Plo Isabelle, Bellanné-Chantelot Christine. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.. Blood. 2014. DOI: 10.1182/blood-2013-05-504555.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.